ClinicalTrials.gg
CompletedNCT04398862Updated Nov 19, 2026

Pulmonary Health in Children With Down Syndrome

An observational study in Down Syndrome and Dysphagia, Oropharyngeal, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Colorado, Denver · Observational

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
63
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Down Syndrome by University of Colorado, Denver — 4 open to participants now, 4 under way, 1 of them phase 3. Down Syndrome · University of Colorado, Denver.

Started
2020
with 1 other
Observational
5 of 12
2 open now
Registered
8th of 12
by date

Among the 12 studies in Down Syndrome by University of Colorado, Denver, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 8th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

4 of the 12 studies in Down Syndrome by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Down Syndrome by University of Colorado, Denver, or all of them as a file.
02

Study summary

The goal of the study is to learn more about tests that can assess lung health in children with Down syndrome.

03

Conditions studied

  • Down Syndrome
  • Dysphagia, Oropharyngeal

Keywords

  • oscillometry
  • spirometry
  • outcomes
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 3-18 years (inclusive) with a diagnosis of Down syndrome who have had a swallow study in the previous 5 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3 to 18 years, inclusive, at time of consent
  • Diagnosis of Down syndrome/trisomy 21 or mosaicism
  • Able to walk
  • Had a swallow study (video fluoroscopic swallow study or fiberoptic endoscopic evaluation of swallowing) performed within 5 years of consent date

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • Nonambulatory
  • Have a tracheostomy or other known severe glottic or subglottic obstruction that would significantly affect the results of testing
  • Have a significant acute respiratory illness, defined as treatment with , antibiotics, or an increase in supplemental oxygen
  • have a medical illness that would a)increase the risk the participate would incur by participating in the study, b) interfere with the outcomes of the study, or c) interfere with the performance of study participants
  • Have a severe behavioral problem that would interfere with the performance of study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
63 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Children with Down syndrome and aspiration

    Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.

  • Children with Down syndrome without aspiration

    Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.

06

What researchers measure

Primary outcomes

  1. Total airway resistance

    Airway resistance (R5) measured using forced oscillation technique at 5 Hertz

    Time frame: Baseline

  2. Airway reactance

    Airway reactance (X5) measured using forced oscillation technique at 5 Hertz

    Time frame: Baseline

Secondary outcomes

  1. Change in total airway resistance after albuterol

    Airway resistance (R5) measured using forced oscillation technique at 5 Hertz before and after administration of albuterol

    Time frame: Baseline

  2. Change in airway reactance after albuterol

    Airway reactance (X5) measured using forced oscillation technique at 5 Hertz before and after administration of albuterol

    Time frame: Baseline

  3. Health-related quality of life, as measured by the Pediatric Quality of Life Inventory

    The Pediatric Quality of Life Inventory (PedsQL) assesses four domains of quality of life. Results are converted to a score from 0-100, where low numbers are low quality of life and higher numbers is better quality of life.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2025, 61 months.

Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 61 months is above that.

Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2024 → Oct 2025 and completion Dec 2024 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2020
First posted
May 21, 2020
StartActual
Aug 21, 2020
Primary completionActual
Oct 20, 2025was Aug 2024
CompletionActual
Oct 20, 2025was Dec 2024
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Aug 30, 2024→Oct 20, 2025 (actual)
Nov 19, 2026
Study completion
Dec 30, 2024→Oct 20, 2025 (actual)
Nov 19, 2026
Enrollment
75 (estimated)→63 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Aug 30, 2024→Oct 20, 2025 (now actual)
    Study completion Dec 30, 2024→Oct 20, 2025 (now actual)
    Enrollment 75 (estimated)→63 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04398862
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Aug 21, 2020
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Nov 19, 2026

Study contacts

Emily DeBoer, MD, MSCS
principal investigator · University of Colorado, Denver

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion